InvestorsHub Logo
Followers 18
Posts 2369
Boards Moderated 0
Alias Born 01/09/2012

Re: johnking29 post# 24842

Saturday, 01/25/2014 3:03:39 PM

Saturday, January 25, 2014 3:03:39 PM

Post# of 425975
"YET they did approve Vascepa for treating Acute Pancreatitus YET that was not Amarins reason for selling Vascepa!"

But again, that's because everyone in the scientific community knows and understands that Very High TG's >1000 mg/dl, is a serious health concern that needs to be addressed and corrective action for TG's in that range is by taking drugs, according to both NCEP and VA.

The problem with TG's in the 200-499 range is that there is no agreement in the scientific community that this level represents a serious health concern, or at least, a definite tie to a serious health concern.

As an example of this disagreement in the scientific community, look at the NCEP/VA treatment guidelines given for a TG 200-499 level (see tables on pg 12 of the link provided below) and you will understand why the FDA is not motivated to approve any Omega 3 type product for TG's in the 200-499 mg/dl level:

http://www.utexas.edu/pharmacy/divisions/pharmaco/rounds/ramirez09-13-2013.pdf


DISCLAIMER - HIGH RISK/REWARD - POSTS ON THIS BOARD MAY OR MAY NOT BE FACTUAL

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News